Mounjaro Weight Loss Injection
Images for illustration purposes only. Brands may vary.
Fastest delivery available: 11/12/2023
For more information on our delivery times, please click here
***PLEASE NOTE: MOUNJARO IS NOT CURRENTLY LICENSED FOR WEIGHT LOSS, WE DO NOT SELL MOUNJARO- THIS PAGE IS TO BE USED FOR INFORMATION PURPOSES ONLY***
Mounjaro™ is a once-weekly injectable weight loss aid that is often prescribed when other weight loss efforts have been ineffective. It is only available on prescription.
We provide confidential follow-up and advice to all patients on their weight loss journey.
**Mounjaro is not yet licensed for sale in the UK however Cloud Pharmacy will be working with the pharmaceutical provider to treat patients with the drug once it is fully approved. Our clinical team are well trained on Mounjaro and are happy to help with any queries.**
To learn more about Mounjaro, please email us with the subject 'MOUNJARO" at:
- Once Weekly Injection
- Clinically Proven
- Not yet Licensed for Weight Loss
- No Hidden Costs
Buy Mounjaro™ Online UK
Mounjaro™ has recently been approved by the United States medicines regulator, the FDA, for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Like the Wegovy weight loss pen it is an injection that can be used to suppress your appetite and therefore aid in your weight loss journey. Studies showed that Mounjaro helped people lose an additional 12 pounds than the active ingredient Semaglutide (Wegovy™).
When available in the UK, you will be able to order and buy Mounjaro Weight Loss pens online from our UK registered online pharmacy and prescribing service. The availability date is unknown at this stage however Wegovy is a similar drug that is licensed for weight loss in the UK.
What is Mounjaro™ Weight Loss Injection?
Mounjaro™ is a prescription-only weight loss injection containing the active ingredient Mounjaro™ Tirzepatide. This is a registered trademark to Eli Lilly who are an american based pharmaceutical company.
The Mounjaro™ (Tirzepatide) injection is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also have weight-related medical problems (e.g high blood pressure, type-2-diabetes, high cholesterol) to help them lose weight and keep the weight off.
- Mounjaro™ should only be used with a reduced calorie meal plan and regular exercise. Mounjaro™ alone will not reduce your weight if taken alone without any other life style adjustments.
- Mounjaro™ contains Tirzepatide, a GLP-1 receptor agonist & GIP receptor agonist and should NOT be used in conjunction with other GLP-1 agonists such as Saxenda or Ozempic or Wegovy.
- There is insufficient data regarding whether taking Mounjaro™ in conjunction with other prescription, over-the-counter or herbal weight loss products is safe and/or effective.
How Does Mounjaro™ Work?
Mounjaro™ (Tirzepatide) is a self-injectable weight loss treatment. It containts the active ingredient Tirzepatide which is very similar to a naturally occuring hormone in the human body called Glucagon-Like Peptide 1 (GLP-1), which belongs to a family of hormones in the body called incretins.
After a meal GLP-1 is naturally released from your intestines to help regulate your blood sugar levels and reduce the amount of glucagon in your body. Glucagon is a naturally occurring hormone that works by inhibiting the action of insulin. As a result, it makes you feel less hungry, slows down the emptying of your stomach and makes you feel 'fuller' for longer.
In summary, Mounjaro™ 'tricks' your body into producing more GLP-1 and therefore sends signals to your brain that you are full and do not need to eat.
Can Mounjaro™ Help me Lose Weight?
The second phase 3 clinical trial for Mounjaro™ conducted by Eli Lilly and Company saw 900 patients with with type 2 diabetes and BMI greater than 27 kg/m2-29.9 kg/m2. Patients received Mounjaro™ or placebo in addition to instruction for a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week) throughout the trial.
The trial resulted in a satistically significant reduction in body weight when compared to the placebo. The trial showed that there was an average reduction of 15.7% in body weight in patients taking Mounjaro™ vs 3.3% reduction in body weight for those taking the placebo.
The results also indicated that after 72 weeks on Mounjaro™, over 80% of patients lost 5% or more of their body wieght. In the placebo group, 30% of patients lost 5% or more. Further clinical trials were also carried out in participants who did not have Type 2 diabetes, which showed statistically significant reductions in body weight.
Mounjaro™ Vs Saxenda
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Saxenda® should be used with a reduced-calorie meal plan and increased physical activity.
Both Mounjaro™ and Saxenda® are GLP-1 receptor agonists, and are part of the same family of injectable hormone like drugs, however the main difference between the two is that Saxenda® is administered once DAILY, whereas Mounjaro™ is administered once WEEKLY.
Mounjaro™ Vs Wegovy®
Tirzepatide (Mounjaro) is a type of medication that belongs to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. This group of medications is primarily used in the treatment of type 2 diabetes.
Mounjaro works by imitating the effects of gut hormones that are secreted by endocrine cells following a meal, such as GLP-1 and GIP, which help control regulation of blood sugar. Mounjaro helps to stimulate the release of insulin, reduces the overall production of glucagon, (a hormone that raises blood sugar), slows down gastric emptying and promotes the feeling of fullness (satiety).
Mounjaro has shown promising levels of efficacy for weight loss in clinical trials. In Phase 2 trials involving subjects who were either obese or overweight, Mounjaro led to significant reductions in body weight compared to the placebo and other comparator treatments. Mounjaro is typically administered once a week, by subcutaneous injection.
For example, in a trial called SURPASS-1, Mounjaro achieved an average weight loss of approximately 14% over 52 weeks. In another study called SURMOUNT-1, subjects that were treated with Mounjaro experienced an average weight loss ranging from 11.3% to 16% across different doses compared to placebo.
Wegovy® is the brand name for semaglutide 2.4mg. Wegovy® is a medication used for chronic weight management in adults who are either obese or overweight, with at least one weight-related comorbidity. It is a GLP-1 RA that helps to regulate appetite and reduce food consumption.
Wegovy® is administered once a week by subcutaneous injection; research has shown that when used in combination with a calorie controlled diet and increased physical activity, significant weight loss is seen.
In a study called STEP 1, subjects that received semaglutide 2.4mg experienced an average weight loss of around 15% compared to the placebo group. The same study also noted improvements in various health markers such as waist circumference and improved glycemic control.
Comparing the efficacy of Mounjaro and Wegovy® directly is challenging because they are different medications with varying dosages and mechanisms of action, however, both of these medications are GLP-1 RA and have shown efficacious effects when managing weight loss in clinical trials.
Clinical trials have demonstrated the efficacy of Mounjaro for weight loss. Studies such as SURPASS-1 and SURMOUNT-1, previously mentioned, have demonstrated that Mounjaro achieved significant weight loss ranging from 11.3% to 16.0% over 52 weeks when compared to a placebo or other treatments in the same category. Mounjaro has also shown potential for weight reduction as well as benefits in glycemic control and cardiovascular risk factors.
Semaglutide 2.4mg (Wegovy®) has also shown notable effectiveness for weight loss in clinical trials. In the STEP program (consisting of trials STEP 1, STEP 2 and STEP 3), participants treated with Wegovy® experienced substantial weight loss compared to the placebo group. During STEP 1, the average weight loss was approximately 15% over 68 weeks.
Whilst both Mounjaro and Wegovy® have demonstrated efficacious results when promoting weight loss, the specific extent of weight reduction and individual response can vary amongst individuals. Factors such as adherence to treatment, lifestyle modifications and baseline characteristics can influence the outcome or results.
Mounjaro™ Vs Orlistat
Through clinical trials, Orlistat was proven to block around one-third of all fat consumed with meals. Working directly in the stomach, Orlistat can help to make weight loss more effective than with a healthy diet and increased exercise alone.
Orlistat is prescription only, the body needs to break down dietary fats into smaller pieces before absorbing them. Orlistat works by obstructing the enzymes that break down the fats in your diet, halting the absorption process.
The obvious difference between Mounjaro™ and Orlistat is that you take Orlistat orally, whereas Mounjaro™ is injected. Orlistat also needs to be taken up to three times a day (after each meal) to get the best out of it meaning it is nowhere near as convenient as Mounjaro™, which is injected once weekly.
Mounjaro™ and Pregnancy
Mounjaro™ may cause fetal harm. When pregnancy is recognized, discontinue Mounjaro™. Discontinue Mounjaro™ in patients at least 2 months before a planned pregnancy.
|How Mounjaro™ Works||Stimulates hormone production and suppresses appetie|
|Efficacy||83% of patients in clinical trial lost 5%+ of their body weight|
|How to Use Mounjaro™||Injection, administered S.C into abdomen, thigh or upper arm once weekly|
|Common Side Effects||Diarrhoea, Nausea, Vomiting, Constipation|
|What is Active Ingredient?||Tirzepatide|
Mounjaro™ Side Effects
The most commonly reported side effects in clinical trials were:
- Nausea (reported in 44% of patients)
- Diarrhoea (reported in 30% of patients)
- Vomiting (reported in 24% of patients)
- Constipation (reported in 24% of patients)
Other side effects included abdominal pain, headache, fatigue, and dizziness.
In animal studies, semaglutide was associated with an increased risk of thyroid tumours. This link has not been determined in humans, but Wegovy should not be taken by people with a personal or family history of thyroid tumours or a condition called MEN-2.
Wegovy has been associated with other serious side effects like acute pancreatitis, gallbladder disease, heart rate increase and kidney injury. See the Wegovy information on side effects for further details.
Mounjaro™ Warning and Precautions
All medications come with risks when taken, even if minimal- the following is a comprehensive list of all potential complications, warning and precautions to be taken into consideration when being prescribed Wegovy™
- Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.
- Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
- Hypoglycemia: Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.
- Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
- Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
- Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.
- Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.
Patient Information Leaflet
Mounjaro™ Weight Loss Injection Patient Information Leaflet
For more information about Wegovy™, please take a look at the information leaflet below. It is important you read the Patient Information Leaflet (PIL) before using Wegovy™.
Drug Interactions and Side Effects
Mounjaro™ Drug Interactions
Like all medications, Wegovy™ has some drugs that will interact with it and the medication should not be used in this instance.
- The addition of Mounjaro™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Mounjaro™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Mounjaro™.
Mounjaro™ Adverse Reactions
The most common adverse reactions reported involved the digestive system; arenausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.
Confirm Mounjaro Weight Loss Injection treatment selection
|1 x Mounjaro||£999,999,999.00|